P198 Efficacy and safety of secukinumab in ankylosing spondylitis: real-world data from Midlands Ankylosing Spondylitis Collaboration (MASC)
Conclusion This multi-centre retrospective analysis found secukinumab to be clinically effective in 68% of patients with AS. There was significant improvement in BASDAI, VAS and CRP levels at week16. Compared to anti-TNF resistant patients, TNF-Naïve responded better to secukinumab, although both showed go od clinical improvement. These findings support the use of secukinumab in the treatment of AS, as a first line therapy or for those who have failed anti-TNF therapy. Safety signals observed in the real-word data set were consistent with those seen in the clinical trials and the Summary of Product Ch aracteristics.Disc...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P197 Evaluating the patient experience of the Barts Health MySpA app for axial spondyloarthritis and psoriatic arthritis
Conclusion MySpA is well received by patients with axSpA and PsA at Whipps Cross Hospital as a resource where they find specialist support, information and exercise guidance to empower management. It provides a useful virtual tool to assist patients take control of their arthritis and track and monitor thei r condition and has been particularly useful in this regard during the Covid pandemic. Patients used the facility to complete and share their assessment results and journal logs virtually with their healthcare team. However, continual awareness of MySpA amongst patients and clinicians is required to enable the opportu...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P196 Secukinumab provides sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 5year results from the Phase3 FUTURE 2 study
Conclusion Analysis of 78 TJC/76 SJC scores demonstrated that treatment with secukinumab significantly reduced joint tenderness and swelling at Week 24, which were sustained over 5 years, irrespective of TNFi history/concomitant MTX use.Disclosure I. McInnes: Grants/research support; Research grants, consultation fees, or speaker honoraria: AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB.H. Chinoy: Grants/research support; Research grants, travel grants, consultancy or speaker honoraria: AbbVie, Amgen, Biogen, BMS, Janssen, Lilly, Novartis and UCB.D. Asquith: Shareholder/stock ownership; Employee ...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P195 Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PsA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomised open-label study
Conclusion In pts with active PsA, a significantly higher proportion of IXE-treated pts achieved the combined ACR50+PASI100 endpoint, and PASI100 at wk 52 vs. ADA, regardless of baseline PsO severity. ACR50 response at wk 24 and 52 was not influenced by IXE dosing. Faster improvements in MDA and DAPSA remis sion were observed with IXE than with ADA. These results were consistent with the overall SPIRIT-H2H population.Disclosure L. Kristensen: Consultancies; LE. Kristensen is a consultant for Amgen, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Forward Pharma, Janssen, Merck and Co., Novartis, Pfizer, UC...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P194 Response to ixekizumab by C-reactive protein level in patients with aadiographic axial spondyloarthritis: results from the COAST-V (biological-naïve) and COAST-W (TNF-α inhibitor-experienced) trials at 52 weeks
Conclusion A higher proportion of ASAS40 responders was observed in IXE treated arms versus PBO among bDMARD-naïve and TNFi-experienced pts with r-axSpA when the CRP cutoff of 10mg/L was evaluated, and the responses were consistent through Wk52. Furthermore, similar proportions of pts achieved BASDAI50 and SF-36 responses within each patient population regardless of the BL CRP cutoff evaluated.Disclosure J.D. Reveille: None.P. Rahman: None.D.M. Sandoval Calderon: Shareholder/stock ownership; D. Sandoval Calderon is a shareholder and employee of Eli Lilly and Company.T. Muram: Shareholder/stock ownership; T. Muram is a...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis
Conclusion In this analysis, patients who did not respond to ADA but subsequently responded to IXE exhibited overall lower levels of inflammation, as measured by CRP and MRI of the spine or sacroiliac joints, compared with patients who responded on ADA and also after switching to IXE. Along with comparative findings in patients who continuously received IXE and responded at both wks16 and 52 or wk52 only, these data indicate that IXE is efficacious in patients with active AS irrespective of inflammation level, assessed by CRP and MRI. Alternatively, lower baseline inflammation may be a predictor of de layed response.Disc...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P192 Secukinumab provides rapid and sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 2-year results from the Phase 3 FUTURE 5 study
Conclusion Secukinumab provided rapid improvements in TJC and SJC at Week 16, which were sustained through Week 104, irrespective of TNFi history/concomitant MTX use. P192 Table 1:Selected baseline characteristics and 78 TJC and 76 SJC Results at Week 104Selected baseline characteristicsVariableSEC 300 mg (N = 222)SEC 150 mg (N = 220)SEC 150 mgno LD (N = 222)PBO (N = 332)Mean adjusted 78 TJC scoreTotal population19.821.221.821.2Mean adjusted 76 SJC scoreTotal population10.012.111.911.778 TJC and 76 SJC Results at Week 104EndpointSECPBO-SEC300 mg SC(N = 100)150 mg SCaa(N = 100)150 mg SCno LDbb(N = 222)300 mg SC (N = 153...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P191 Secukinumab demonstrates a consistent safety profile in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis over long term: updated pooled safety analyses
Conclusion Secukinumab was well tolerated in this long-term analysis of patients with PsO, PsA and AS across clinical trials and post-marketing surveillance, with a safety profile consistent with previous reports (Deodhar, 2019). P191 Table 1:Selected adverse events of interest with secukinumab across poo led clinical trialsVariablePsOPsAASSEC N = 8,819SEC N = 2,678SEC N = 1,140Exposure (days),mean (SD)623.9 (567.7)816.2 (580.7)1130.1 (583.0)Death, n (%)14 (0.2)11 (0.4)9 (0.8)Selected adverse events of interest, EAIR (95% CI)Serious infectionsa1.4 (1.2-1.6)1.8 (1.5-2.2)1.2 (0.9-1.6)Candida infectionsbb2.9 (2.7-3.2)1.5 ...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P190 Secukinumab improves back pain, morning stiffness, fatigue and physical function in tumour necrosis factor inhibitor-naive patients with non-radiographic axial spondyloarthritis: results from a randomised controlled Phase 3 study
Conclusion Secukinumab provided clinically meaningful improvement in back pain, morning stiffness, fatigue and physical function in TNFi-naive patients with nr-axSpA over 52 weeks.Disclosure H. Marzo-Ortega: Consultancies; H.M-O. is a consultant for AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB. Member of speakers ’ bureau; H.M-O. is a member of speakers' buraeu for AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB. Grants/research support; H.M-O. has received research support from Janssen and Novartis.A. Deodhar: Consultancies; A.D. is a consultant for AbbVie, Amgen, Boehringer Ingelheim,...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P189 Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study
Conclusion In this pre-specified analysis, secukinumab provided higher responses compared with adalimumab in achievement of combined improvement in joint and skin disease (combined ACR50 and PASI100 response) and in skin-specific endpoints (PASI100 and absolute PASI score ≤3) at Week 52. P189 Table 1:Sk in-specific outcomes at Week 52Endpoints, % responseSEC 300 mg (N = 215)ADA 40 mg (N = 202)P value (unadjusted)PASI10046300.0007Combined ACR50 and PASI10031190.0087Absolute PASI score ≤379650.0015P value vs ADA; unadjusted P values are presented. Multiple imputation was used for handling missing d ata. ADA, adalimum...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P188 Secukinumab provides significant improvement of spinal pain and lowers disease activity in patients with axial spondyloarthritis: 24-week results from a randomised controlled Phase 3b trial
Conclusion Secukinumab provided rapid, significant improvement in spinal pain and led to low disease activity in axSpA patients. Secukinumab dose escalation might be beneficial for patients not responding fully to the starting dose. P188 Table 1:Spinal pain and ASDAS-CRP scores at Weeks 8 and 24Week 8SEC 150 mg (N = 285)PBO (N = 95)Change from baseline in spinal pain NRS score (total), mean (SD) [n]-2.6 (2.5) [279]-1.5 (2.2) [92]Change from baseline in ASDAS-CRP score, mean (SD) [n]-1.2 (1.0) [271]-0.5 (0.8) [89]Week 24Active treatment group (SEC treatment starting at baseline)PBO switchers group (S EC treatment starti...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P187 Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study
Conclusion Secukinumab demonstrated a rapid and significant decrease in synovitis over 12 weeks (per GLOESS), and superior efficacy on ACR20/50 responses and SPARCC enthesitis vs placebo at Week 12 in biologic-naive patients with PsA. The safety profile of secukinumab was consistent with previous reports.Disclosure M. D'Agostino: Honoraria; M-A.D has received speaker/consultancy fees from Sanofi, Novartis, BMS, Celgene, Roche, AbbVie, UCB and Eli Lilly.G. Schett: Honoraria; G.S. has received honoraria from AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Roche and UCB.A. L ópez Rodríguez: Corporate appointments; A.L.R...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P186 Secukinumab effectiveness and safety in patients with active psoriatic arthritis or ankylosing spondylitis: interim analysis of an observational study in the real-world setting
Conclusion Patients in SERENA had long-standing disease with more than half previously treated with biologics, most of whom had discontinued treatment due to lack of efficacy. SEC showed sustained effectiveness, a high retention rate and favourable safety profile in PsA and AS patients in the real world ove r 1 year of observation. Incomplete data due to lack of rigorous monitoring (an intrinsic weakness of observational studies) must be considered when interpreting real-world findings.Disclosure K. Gaffney: Grants/research support; Research grants, consultancy fees and/or speaker fees from AbbVie, Celgene, Lilly, Pfiz...
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P185 Does BASDAI score correlate to MRI changes in ankylosing spondylarthritis?
Conclusion BASDAI score did not statistically correlate with the severity of inflammation as objectively observed on MRI. Only inflammatory back pain and anti-TNF therapy correlated with MRI disease activity. There was no difference in clinical features including HLA-B27 between patients with active and ina ctive MRI. Thus, BASDAI as a criterion for biologic therapy may need re-considering.Disclosure N. Jain: None.S. Byravan: None.J. Stairs: None.W. Rennie: None.M. Arumugam: Other; Speaker and Conference Fee MSD, Novartis, Abbvie. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
P150 Hand-held dynamometry may provide a valid and objective method of muscle strength quantification in adult inflammatory myopathy: results from clinical practice in a tertiary centre
Conclusion This study indicates that HHD may provide an inexpensive, user-friendly method of strength assessment in IIM patients, providing accurate insights into function, strength and global activity. Undertaking HHD in clinic and by a specialist physiotherapist allows for stratified, personalised rehabil itation intervention. Following future validation, HHD could form a method of objective muscle strength assessment, thus focusing IIM clinical care and research.Disclosure W.J. Gregory: Honoraria; W.G. has received honoraria from Abbvie, Pfizer and UCB.A. Oldroyd: None.H. Chinoy: None. (Source: Rheumatology)
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research
